肝切除术前门静脉栓塞的自然史:23年意向性治疗结果分析
该回顾性研究纳入1993至2015年间在本中心接受大范围肝切除术前门静脉栓塞(PVE)的431例患者,评估PVE的安全性和有效性。PVE相关并发症发生率为16.7%,死亡率0.2%;96%患者栓塞后达到足够未来肝剩余体积,但仅66%最终接受计划肝切除,疾病进展是最常见不可切除原因(67%)。肝外胆道肿瘤患者不可切除率显著高于其他实体瘤(45.1% vs 31.4%,P=0.019)。
要点
- PVE后仅66%患者最终接受肝切除,34%未手术。
- 疾病进展是PVE后不可切除的最常见原因(67%)。
- 肝外胆道肿瘤PVE后不可切除率显著更高(45.1% vs 31.4%)。
核心结论
- PVE后34%患者未接受肝切除,胆道肿瘤脱落率更高且肿瘤进展阻止根治性切除的机会更大。
- PVE相关并发症在5%患者中阻止了根治性切除,多学科严格选择至关重要以避免PVE过度使用。
研究设计与样本
- 单中心高容量肝胆中心回顾性分析,纳入1993至2015年间接受大范围肝切除术前PVE的患者431例。
主要发现
- PVE并发症发生率和死亡率分别为16.7%和0.2%。
- 经皮同侧入路并发症显著少于对侧入路(10.3% vs 19.4%,P=0.024)。
- 96%患者栓塞后达到足够未来肝剩余体积,但仅66%最终接受计划肝切除。
- 疾病进展是不可切除最常见原因(67%)。
- 肝外胆道肿瘤患者不可切除率显著高于其他实体瘤(45.1% vs 31.4%,P=0.019)。
临床怎么用
- PVE前应多学科严格评估,避免在技术上可切除患者中过度使用PVE。
- 对肝外胆道肿瘤患者PVE后需密切监测肿瘤进展,警惕高脱落风险。
局限性
- 回顾性单中心研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Portal vein embolization (PVE) use is nowadays debated due to the risk of technical or biological unresectability after the period of time needed to achieve future liver remnant (FLR) hypertrophy. We evaluated the safety and efficacy of PVE in a single high-volume hepatobiliary center, with emphasis in the feasibility to achieve tumor resection. METHODS: Patients undergoing PVE before major hepatectomy at our institution between 1993 and 2015 were retrospectively analyzed. RESULTS: A total of 431 patients formed the study population. Morbidity and mortality rates of PVE were 16.7% and 0.2% respectively. Morbidity was similar between percutaneous and ileocolic approaches or between histoacryl and ethanol as embolization materials (P > 0.05). On the contrary, the percutaneous ipsilateral approach was associated with significantly less complications than the contralateral approach (10.3% vs 19.4%; P = 0.024). Almost all patients (96%) achieved sufficient FLR volume after embolization, but only 66% finally underwent planned liver resection. Disease progression was the most common cause of unresectability (67%). Patients with extrahepatic biliary tumors experienced significantly higher unresectability rates compared to other entities (45.1% vs 31.4%; P = 0.019). CONCLUSION: PVE was not followed by hepatectomy in 34% of our patients. Biliary tumors displayed the higher dropout rates after PVE and the higher chances of tumor progression preventing curative resection. Although PVE may be performed with acceptable morbidity, PVE-related complications prevented curative resection in 5% of patients. Careful multidisciplinary selection is crucial to avoid PVE overuse in technically resectable patients who will experience a not negligible risk of futile use and non-therapeutic laparotomy.
引用
- Alvarez FA, Castaing D, Figueroa R, et al. Natural history of portal vein embolization before liver resection: a 23-year analysis of intention-to-treat results. Surgery. 2018. PMID: 29502872. doi:10.1016/j.surg.2017.12.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。